The United States built its global scientific dominance on a foundational principle: that research funding should follow the best ideas, not the preferred politics of the moment. That principle is now under direct and deliberate assault. A 412-page proposed rule from the White House Office of Management and Budget, published in late May and slated to take effect October 1, would fundamentally restructure how the federal government awards research grants — stripping authority from career scientists and peer reviewers and placing it in the hands of senior political appointees accountable not to scientific merit, but to presidential priorities.
The rule, advanced by OMB Director Russell Vought, codifies and expands upon a series of Trump executive orders targeting federally funded research. It declares that “senior appointees” at federal agencies must sign off on awards before they are granted, that ongoing grants may be terminated at any time if deemed “inconsistent” with agency priorities, and that researchers may not use federal funds to attend conferences or pay journal publication costs without explicit pre-approval. Critically, the proposal asserts that “peer review remains advisory and does not replace agency discretion” — a direct statement of intent to subordinate scientific judgment to political gatekeeping.
The research community’s response has been swift and alarmed. More than 70,000 public comments were submitted before the July 13 deadline. Marcia McNutt, president of the National Academy of Sciences, put the stakes plainly at her annual State of Science Address: “The proposal is that politicians will decide what research to fund, what meetings scientists are allowed to attend, and whether and where the results can be published.”
Despite this groundswell, the administration has shown no sign of retreat. When researchers and scientific organizations including the American Chemical Society requested a 45-day extension of the comment period to allow for more thorough public input, Vought refused. At a June 30 House Appropriations Committee hearing, ranking Democrat Rosa DeLauro characterized the rule as placing research funding “at the whims of the President’s policy priorities,” substituting “the current standard of evidence in science in favour of political tests based on ideology.” Vought dismissed these characterizations as a misconstruing of the proposal’s intent.
An analysis by Stand Up for Science examining over 10,000 active clinical research studies estimates that the rule’s provisions on international collaborations and policy alignment could render nearly half of those trials ineligible for continued funding. “All future clinical trials would be at risk of cancellation under the proposal,” the organization concluded, “as the rule would put political appointees in charge of funding decisions and give them the ability to cancel funding at any time.”
Perhaps most troubling is the behavior of the National Science Foundation, which has already released proposed amendments to its grant policies in anticipation of the OMB rule — before the public comment period on that rule has even closed. Representative Zoe Lofgren, the top Democrat on the House Science Committee, wrote to NSF’s acting director demanding the proposed amendments be rescinded, calling the move “a clear sign that the Administration in general, and NSF specifically, have no interest in legitimately considering the input of the impacted community.” NSF has also seen a steep drop in grant awards compared to previous years, with one congressional member suggesting that White House Office of Science and Technology Policy political appointees are now approving grant awards — a claim NSF declined to address.
Neal Lane, who led NSF under President Clinton before serving as his science adviser, identified the core danger precisely: “NSF makes grant decisions based on the deep knowledge of experts in the field, not on whether it meets an ideological agenda. That’s what merit review is all about. Replacing it with top-down decision-making will destroy that process and result in bad science being funded.”
Federal research funding underpins pandemic preparedness, drug development, surveillance infrastructure, and the clinical trials pipeline that produces future treatments. A system in which political alignment determines which science gets done is one in which the nation’s health security becomes contingent on ideology rather than evidence. Former NIH program officer Elizabeth Ginexi framed it starkly: what OMB is proposing is not grants management reform — it is “a vehicle for complete political control of science … over every stage of the federal science funding lifecycle.” That is a threat to the national interest, not merely to the academic community, and it warrants exactly that level of serious, sustained attention.
Sources and further reading:
NSF proposes grant policy updates based on OMB rule – AIP
Agency Information Collection Activities — NSF Guidance on Financial Assistance – Regulations.gov
Trump administration stands by controversial OMB proposal despite growing resistance – Chemistry World
Latest White House move to politicise science funding provokes outrage among research leaders – Chemistry World
Health equity researchers fear unseen level of scrutiny under White House proposal – STAT News
White House seeks to tighten political oversight of grantmaking – Science
This article was researched and sourced by Global Biodefense editors and reported with Claude AI assistance for drafting and editing.